Psychedelic Science & Policy
@psysci.pyxorium.com
Psychedelic Science and Policy from across the open internet
Monday, November 17, 2025, 1:00-2:00pm (PT) webinar
"As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments?"
"As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments?"
After Schedule I: Federal Psychedelic Rescheduling and the Impact on State Law
www.law.berkeley.edu
November 1, 2025 at 4:00 PM
Monday, November 17, 2025, 1:00-2:00pm (PT) webinar
"As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments?"
"As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments?"
Webinar
Monday, October 20, 2025
10AM Eastern
Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine.
Monday, October 20, 2025
10AM Eastern
Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine.
Webinar Registration - Zoom
Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine. Their conversation will explore practical strategies for patient education and innovative approaches to expanding mental health care capacity. Attendees will gain actionable insights to navigate emerging treatments and support informed conversations with patients. A live Q&A will follow the discussion.
us06web.zoom.us
October 15, 2025 at 6:44 PM
Webinar
Monday, October 20, 2025
10AM Eastern
Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine.
Monday, October 20, 2025
10AM Eastern
Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine.
"In the present study, the magnitude of the [Oceanic Boundlessness] experience induced by [high ventilation breathwork with music] was comparable to that elicited by serotonergic psychedelic substances, including psilocybin and lysergic acid diethylamide (LSD)" Aug 2025 PLoS One 20(8): e0329411
Neurobiological substrates of altered states of consciousness induced by high ventilation breathwork accompanied by music
The popularity of breathwork as a therapeutic tool for psychological distress is rapidly expanding. Breathwork practices that increase ventilatory rate or depth, facilitated by music, can evoke subjec...
journals.plos.org
September 5, 2025 at 1:37 PM
"In the present study, the magnitude of the [Oceanic Boundlessness] experience induced by [high ventilation breathwork with music] was comparable to that elicited by serotonergic psychedelic substances, including psilocybin and lysergic acid diethylamide (LSD)" Aug 2025 PLoS One 20(8): e0329411
Starting in October 2025, the US Department of Defense will test Service members for psilocin (psilocybin mushroom) consumption due to "the risk of impairment and subsequent deterioration of security, military fitness, readiness, good order and discipline" (per linked DOD Memorandum)
Service Members to Be Tested for Hallucinogenic Psilocin Found in ‘Magic Mushrooms’
The Pentagon will begin testing service members for psilocin, the hallucinogenic compound produced when psilocybin mushrooms, also known as magic
www.sofx.com
September 2, 2025 at 2:13 PM
Starting in October 2025, the US Department of Defense will test Service members for psilocin (psilocybin mushroom) consumption due to "the risk of impairment and subsequent deterioration of security, military fitness, readiness, good order and discipline" (per linked DOD Memorandum)
Reposted by Psychedelic Science & Policy
A Utah-based faith group is suing for the right to use psilocybin mushrooms as part of its religious practices, arguing that criminalization violates religious freedom protections. The case could set a significant precedent in balancing state drug laws with religious liberty.
Judges rules in favor of Utah faith group seeking to use psychedelic mushrooms
The first-of-its-kind case is putting Utah’s new religious freedom law to the test
buff.ly
August 7, 2025 at 3:11 AM
A Utah-based faith group is suing for the right to use psilocybin mushrooms as part of its religious practices, arguing that criminalization violates religious freedom protections. The case could set a significant precedent in balancing state drug laws with religious liberty.
State psychedelic legalization and policy roundup, August 2025
Arizona, Colorado, Louisiana, Massachusetts, Michigan, Mississippi, Oregon
Arizona, Colorado, Louisiana, Massachusetts, Michigan, Mississippi, Oregon
State psychedelics legalization and policy roundup — August 2025
Arizona allocates funding for ibogaine research, Reason Foundation to testify at Mississippi informational hearing about ibogaine, and more.
reason.org
August 12, 2025 at 6:13 PM
State psychedelic legalization and policy roundup, August 2025
Arizona, Colorado, Louisiana, Massachusetts, Michigan, Mississippi, Oregon
Arizona, Colorado, Louisiana, Massachusetts, Michigan, Mississippi, Oregon
"[P]articipants reported improvements in their sleep, physical ability, cognitive function, social ability, fatigue, anxiety, and the impact of pain on their everyday lives. Three months later, researchers found [...] the reductions around the impacts of pain became statistically insignificant."
Oregon study shows psilocybin therapy helped low-income people fight depression
Psilocybin therapy can help low-income people suffering from depression, according to a new study from Oregon researchers.
www.klcc.org
August 7, 2025 at 2:45 PM
"[P]articipants reported improvements in their sleep, physical ability, cognitive function, social ability, fatigue, anxiety, and the impact of pain on their everyday lives. Three months later, researchers found [...] the reductions around the impacts of pain became statistically insignificant."
"Our study hints at an exciting avenue for future research to combine neuromodulation with psychedelics to precisely target specific circuits for neural plasticity." bioRxiv 2025 August
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the medial frontal cortex in mice. The dendritic spines would ...
www.biorxiv.org
August 7, 2025 at 2:37 PM
"Our study hints at an exciting avenue for future research to combine neuromodulation with psychedelics to precisely target specific circuits for neural plasticity." bioRxiv 2025 August
Dr. Lawrence Leeman of the University of New Mexico describes how the REKINDLE clinical trial will test the effectiveness of RE104 (a synthetic prodrug similar to psilocybin) in treating patients who have received a life-altering disease diagnosis.
UNM Scientists Test Experimental Psychedelic Drug to Alleviate the Emotional Toll of a Life-Threatening Diagnosis
University of New Mexico researchers are joining a multi-site clinical trial of an experimental psychedelic drug intended to alleviate the mental suffering many patients experience when they receive a...
hscnews.unm.edu
August 6, 2025 at 1:24 PM
Dr. Lawrence Leeman of the University of New Mexico describes how the REKINDLE clinical trial will test the effectiveness of RE104 (a synthetic prodrug similar to psilocybin) in treating patients who have received a life-altering disease diagnosis.
Reposted by Psychedelic Science & Policy
Check out our latest paper in Nature Neuroscience (rdcu.be/ey7yk). This was a great collaboration with some very surprising results! Seems that a glutamate burst and proximate IEG expression might not be necessary for structural neuroplasticity induced by 5-HT2A partial agonists.
August 5, 2025 at 12:52 PM
Check out our latest paper in Nature Neuroscience (rdcu.be/ey7yk). This was a great collaboration with some very surprising results! Seems that a glutamate burst and proximate IEG expression might not be necessary for structural neuroplasticity induced by 5-HT2A partial agonists.
Reposted by Psychedelic Science & Policy
Greg Watry of @ucdlands.bsky.social wrote a wonderful article about the #UCDavisIPN's @natureportfolio.nature.com most recent Neuroscience publication. Find out why our associate director, John A. Gray said, "Science is full of surprises."
Read the article here: www.ucdavis.edu/news/psyched...
Read the article here: www.ucdavis.edu/news/psyched...
Psychedelics and Non-hallucinogenic Analogs Work Through the Same Receptor, Up to a Point
Understanding exactly how psychedelics promote new connections in the brain is critical to developing targeted, non-hallucinogenic therapeutics that can treat neurodegenerative and neuropsychiatric di...
www.ucdavis.edu
August 5, 2025 at 3:44 PM
Greg Watry of @ucdlands.bsky.social wrote a wonderful article about the #UCDavisIPN's @natureportfolio.nature.com most recent Neuroscience publication. Find out why our associate director, John A. Gray said, "Science is full of surprises."
Read the article here: www.ucdavis.edu/news/psyched...
Read the article here: www.ucdavis.edu/news/psyched...
"With growing attention towards psilocybin treatment, the associated risk of medical liability for physicians involved in prescribing psilocybin or facilitating psilocybin treatment becomes increasingly important to study." J Law Med Ethics 2025 July
www.cambridge.org
August 5, 2025 at 2:38 PM
"With growing attention towards psilocybin treatment, the associated risk of medical liability for physicians involved in prescribing psilocybin or facilitating psilocybin treatment becomes increasingly important to study." J Law Med Ethics 2025 July
"Psychedelics such as LSD and DMT, have shown intriguing results in regulating neuroplasticity and inflammation, but their use in [Alzheimer's disease] treatment is still largely experimental and requires rigorous clinical validation." Transl Neurodegener. 2025 July
Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease - Translational Neurodegeneration
Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treat...
translationalneurodegeneration.biomedcentral.com
August 3, 2025 at 2:24 PM
"Psychedelics such as LSD and DMT, have shown intriguing results in regulating neuroplasticity and inflammation, but their use in [Alzheimer's disease] treatment is still largely experimental and requires rigorous clinical validation." Transl Neurodegener. 2025 July
"Filament Health has collaborated with University College London (UCL) in the UK to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies."
Filament Health to supply psilocybin for two Phase II studies
Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.
www.clinicaltrialsarena.com
August 1, 2025 at 2:15 PM
"Filament Health has collaborated with University College London (UCL) in the UK to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies."
Inside Appalachia producer Bill Lynch speaks with Corinne Hazel and Daniel Panaccione about their research on fungi in morning glory plants that make psychedelic ergot alkaloids.
WVU Researcher Discovers Potential Mental Health Treatment Through Psychedelic Fungi - West Virginia Public Broadcasting
A West Virginia researcher is working at the cutting edge of the study of psychedelics. Corinne Hazel is a West Virginia University microbiology student. This spring, she found a fungus that was barel...
wvpublic.org
July 31, 2025 at 2:13 PM
Inside Appalachia producer Bill Lynch speaks with Corinne Hazel and Daniel Panaccione about their research on fungi in morning glory plants that make psychedelic ergot alkaloids.
Alana Hippensteele analyzes issues relevant to psychedelic health care professionals, such as informed consent, standard of care, licensing, data collection, HIPAA conflicts, cybersecurity, breach liability, insurance coverage and reimbursement, and more.
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, re...
www.ajmc.com
July 31, 2025 at 2:03 PM
Alana Hippensteele analyzes issues relevant to psychedelic health care professionals, such as informed consent, standard of care, licensing, data collection, HIPAA conflicts, cybersecurity, breach liability, insurance coverage and reimbursement, and more.
Reposted by Psychedelic Science & Policy
www.drugscience.org.uk/uk-governmen... - light at the end of the tunnel for #psychedelics research and treatment we hope
UK Government supports ACMD plan to enable research with schedule 1 medicines such as psilocybin and MDMA
Despite the resurgence of research into the clinical efficacy and mechanism of action of psychedelic drugs such as such as psilocybin, LSD, DMT, and MDMA they are currently in Schedule 1 of the Misuse...
www.drugscience.org.uk
July 31, 2025 at 7:51 AM
www.drugscience.org.uk/uk-governmen... - light at the end of the tunnel for #psychedelics research and treatment we hope
Dr. Jhilam Biswas speaks on behalf of the Massachusetts Psychiatric Society to express the Society's support for decriminalizing the simple possession of psilocybin.
Massachusetts Psychiatric Society Endorses Bill To Decriminalize Psilocybin Possession
“We are encouraged by the growing body of rigorous research exploring the use of psychedelics, including psilocybin in treating treatment-resistant types of mental illness.” By Jack Gorsline, HorizonM...
www.marijuanamoment.net
July 30, 2025 at 1:53 PM
Dr. Jhilam Biswas speaks on behalf of the Massachusetts Psychiatric Society to express the Society's support for decriminalizing the simple possession of psilocybin.
Reposted by Psychedelic Science & Policy
(29) The Molly Maker: 5 Questions for PharmAla founder Nick Kadysh themicrodose.substack.com/p/the-molly-...
The Molly Maker: 5 Questions for PharmAla founder Nick Kadysh
Kadysh discusses PharmAla’s MDMA and the logistics of the international MDMA supply chain.
themicrodose.substack.com
July 28, 2025 at 5:08 PM
(29) The Molly Maker: 5 Questions for PharmAla founder Nick Kadysh themicrodose.substack.com/p/the-molly-...
Reposted by Psychedelic Science & Policy
Watch three exciting book presentations that Drugreporter recorded at PS25 in Denver, by Timothy Leary’s son, Zach Leary, Wendy Tucker, Ann Shulgin’s daughter and Diego Ugalde.
Extraordinary Books at Psychedelic Science 2025
Watch three exciting book presentations that Drugreporter recorded at PS25 in Denver. Timothy Leary’s son, Zach Leary, presented his new book Your Extraordinary Mind; Wendy Tucker, Ann Shulgin’s daugh...
drogriporter.hu
July 29, 2025 at 11:41 AM
Watch three exciting book presentations that Drugreporter recorded at PS25 in Denver, by Timothy Leary’s son, Zach Leary, Wendy Tucker, Ann Shulgin’s daughter and Diego Ugalde.
"Whether these therapies live up to their billion-dollar potential in mental health and beyond may depend less on the molecules themselves, and more on the industry’s ability to deliver them safely, ethically and at scale."
European Medical Journal, 2025 July
European Medical Journal, 2025 July
After decades of regulatory exile, compounds like MDMA, psilocybin and LSD are re-emerging as pipeline assets.
But will they ever be accepted as traditional therapies?
Discover the latest here: hubs.la/Q03zg0Fl0
But will they ever be accepted as traditional therapies?
Discover the latest here: hubs.la/Q03zg0Fl0
Could psychedelic medicine solve the mental health crisis?
Explore the evolving role of MDMA, LSD and psilocybin in traditional medical research, particularly in the realm of mental health.
hubs.la
July 29, 2025 at 3:03 PM
"Whether these therapies live up to their billion-dollar potential in mental health and beyond may depend less on the molecules themselves, and more on the industry’s ability to deliver them safely, ethically and at scale."
European Medical Journal, 2025 July
European Medical Journal, 2025 July
"Together, these findings indicate that LSD, acutely administered, acts as a rapid-onset antidepressant in naïve rat, but not in naïve mice, through mechanisms involving activation of 5-HT2B receptors." Biomedicine & Pharmacotherapy 2025
LSD's rapid antidepressant effects are modulated by 5-HT2B receptors
Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a great …
www.sciencedirect.com
July 28, 2025 at 3:00 PM
"Together, these findings indicate that LSD, acutely administered, acts as a rapid-onset antidepressant in naïve rat, but not in naïve mice, through mechanisms involving activation of 5-HT2B receptors." Biomedicine & Pharmacotherapy 2025
Reposted by Psychedelic Science & Policy
Two psilocybin studies led by @rosmcalpine.bsky.social, @mjaglinska.bsky.social, @kjedlovszky.bsky.social, @orisshenyan.bsky.social, and others.
www.filament.health/news/filamen...
www.filament.health/news/filamen...
Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London
Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London
www.filament.health
July 24, 2025 at 5:02 PM
Two psilocybin studies led by @rosmcalpine.bsky.social, @mjaglinska.bsky.social, @kjedlovszky.bsky.social, @orisshenyan.bsky.social, and others.
www.filament.health/news/filamen...
www.filament.health/news/filamen...
Reposted by Psychedelic Science & Policy
A psychedelic drug disorganizes cortical traveling waves. Groovy work.
Complex slow waves in the human brain under 5-MeO-DMT
doi.org/10.1016/j.ce...
#neuroscience
Complex slow waves in the human brain under 5-MeO-DMT
doi.org/10.1016/j.ce...
#neuroscience
Redirecting
doi.org
July 25, 2025 at 3:13 PM
A psychedelic drug disorganizes cortical traveling waves. Groovy work.
Complex slow waves in the human brain under 5-MeO-DMT
doi.org/10.1016/j.ce...
#neuroscience
Complex slow waves in the human brain under 5-MeO-DMT
doi.org/10.1016/j.ce...
#neuroscience
Avon, Colorado approves rules for psilocybin healing centers
"The town’s regulations on natural medicine healing centers will go into effect 30 days following the July 22 approval, at which point natural medicine businesses can begin to open in Avon."
report by @vaildaily.bsky.social
"The town’s regulations on natural medicine healing centers will go into effect 30 days following the July 22 approval, at which point natural medicine businesses can begin to open in Avon."
report by @vaildaily.bsky.social
Psychedelic therapy centers can open in Avon beginning in August
Therapeutic centers that use psychedelic compounds to treat patients will be able to open in Avon beginning in August. On Tuesday, Avon finished establishing where and under what limitations natural m...
www.vaildaily.com
July 27, 2025 at 3:43 PM
Avon, Colorado approves rules for psilocybin healing centers
"The town’s regulations on natural medicine healing centers will go into effect 30 days following the July 22 approval, at which point natural medicine businesses can begin to open in Avon."
report by @vaildaily.bsky.social
"The town’s regulations on natural medicine healing centers will go into effect 30 days following the July 22 approval, at which point natural medicine businesses can begin to open in Avon."
report by @vaildaily.bsky.social